# A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

> **NCT05262400** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 192 (actual)

## Conditions studied

- Breast Cancer
- Solid Tumors

## Interventions

- **DRUG:** PF-07220060 + PF-07104091 combination dose escalation
- **DRUG:** PF-07220060 + PF-07104091 combination dose escalation
- **DRUG:** PF-07220060 + PF-07104091 combination dose escalation
- **DRUG:** PF-07220060 + PF-07104091 combination dose escalation
- **DRUG:** PF-07220060 + PF-07104091 combination dose escalation
- **DRUG:** PF-07104091 + PF-07220060 + fulvestrant dose expansion
- **DRUG:** PF-07104091 + PF-07220060 + fulvestrant dose expansion
- **DRUG:** PF-07104091 + PF-07220060 + letrozole dose expansion
- **DRUG:** PF-07220060 + PF-07104091 combination dose escalation
- **DRUG:** PF-07220060 + PF-07104091 combination dose escalation
- **DRUG:** PF-07220060 + PF-07104091 combination dose escalation

## Key facts

- **NCT ID:** NCT05262400
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-14
- **Primary completion:** 2026-08-23
- **Final completion:** 2026-08-23
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05262400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05262400, "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05262400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*